Pegulicianine Acetate
drug drugOn this page
Also known as LUM-015Lum015LUM015 ACETATELumicellLumisight
Summary
Pegulicianine Acetate (CHEMBL4594345) is an approved small molecule; indicated across 3 conditions including breast neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594345 |
| Name | Pegulicianine Acetate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: LUM-015, Lum015, LUM015, LUM015 ACETATE, Lumicell, Lumisight, Pegulicianine acetate, PEGULICIANINE ACETATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02584244 | PHASE1/PHASE2 | RECRUITING | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers |
| NCT02438358 | PHASE1/PHASE2 | COMPLETED | Feasibility Study of Intraoperative Imaging in Breast Cancer |
| NCT04440982 | PHASE2 | TERMINATED | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients |
| NCT01626066 | PHASE1 | COMPLETED | Cathepsin Activatable Fluorescent Probe |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.